04-16-2005, 08:49 PM
|
 |
Registered User
|
|
Join Date: Mar 2005
Posts: 199
Thanks: 0
Thanked 4 Times in 4 Posts
|
|
|
Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic dis
Source:
Ann Hematol. 2005 Mar;84(3):159-66. Epub 2004 Nov 24
Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B.
Medizinische Klinik III, Klinikum der Johann Wolfgang Goethe-Universitat, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany, arndt@rzrm.de.
Anemia of chronic disease (ACD) is a frequent complication of chronic inflammation in rheumatoid arthritis (RA). Recombinant human erythropoietin (rHuEpo) has been shown to be effective in correcting ACD, although with a variable rate of nonresponders. The first aim of this trial was to improve the response to rHuEpo by parenteral iron supplementation in cases of iron-deficient erythropoiesis (IDE). An additional goal was the evaluation of the zinc protoporphyrin content of erythrocytes (ZnPP), the soluble transferrin receptor (sTrfR) serum concentration, and the hemoglobin (Hb) content of reticulocytes (CHr) in stimulated erythropoiesis as diagnostic and prognostic parameters. Thirty RA patients with ACD were treated with subcutaneous 150 IU rHuEpo/kg body weight twice weekly. Intravenous iron supplementation (200 mg iron sucrose once weekly) was added in cases of IDE (n=23), which was defined by the presence of two of three criteria: saturation of transferrin (TrfS) /=10%, and a serum ferritin (Fn) concentration
PMID: 15565327 [PubMed - in process]
|
You are currently accessing this Site as a guest. Please login or register by clicking Here
Linear Mode
